» Articles » PMID: 10692616

Quantitative Estimation of Rare Adverse Events Which Follow a Biological Progression: a New Model Applied to Chronic NSAID Use

Overview
Journal Pain
Specialties Neurology
Psychiatry
Date 2000 Feb 29
PMID 10692616
Citations 116
Authors
Affiliations
Soon will be listed here.
Abstract

Randomised controlled trials (RCTs) alone are unlikely to provide reliable estimates of the incidence of rare events because of their limited size. Cohort, case control, and other observational studies have large numbers but are vulnerable to various kinds of bias. Wanting to estimate the risk of death from bleeding or perforated gastroduodenal ulcers with chronic usage of non-steroidal anti-inflammatory drugs (NSAIDs) with greater precision, we developed a model to quantify the frequency of rare adverse events which follow a biological progression. The model combined data from both RCTs and observational studies. We searched systematically for any report of chronic (>/=2 months) use of NSAIDs which gave information on gastroduodenal ulcer, bleed or perforation, death due to these complications, or progression from one level of harm to the next. Fifteen RCTs (19364 patients exposed to NSAIDs for 2-60 months), three cohort studies (215076 patients redeeming a NSAID prescription over a 3-12 month period), six case-control studies (2957 cases) and 20 case series (7406), and case reports (4447) were analysed. In RCTs the incidence of bleeding or perforation in 6822 patients exposed to NSAIDs was 0.69%; two deaths occurred. Of 11040 patients with bleeding or perforation with or without NSAID exposure across all reports, 6-16% (average 12%) died; the risk was lowest in RCTs and highest in case reports. Death from bleeding or perforation in all controls not exposed to NSAIDs occurred in 18 out of 849489 (0.002%). From these numbers we calculated the number-needed-to-treat for one patient to die due to gastroduodenal complications with chronic (>/=2 months) NSAIDs as 1/((0.69x¿6-16%, average 12%¿)-0.002%))=909-2500 (average 1220). On average 1 in 1200 patients taking NSAIDs for at least 2 months will die from gastroduodenal complications who would not have died had they not taken NSAIDs. This extrapolates to about 2000 deaths each year in the UK.

Citing Articles

Identification of the active constituents and molecular mechanism of Eulophia nuda extract in the treatment of osteoarthritis by network pharmacology, molecular modelling and experimental assays.

Padhee S, Mohanty D, Mohanty S, Sahoo A, Jena S, Patnaik J Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39311920 DOI: 10.1007/s00210-024-03459-z.


Association of long-term use of non-steroidal anti-inflammatory drugs with knee osteoarthritis: a prospective multi-cohort study over 4-to-5 years.

Salis Z, Sainsbury A Sci Rep. 2024; 14(1):6593.

PMID: 38504099 PMC: 10950850. DOI: 10.1038/s41598-024-56665-3.


Investigation of the association of long-term NSAID use with radiographic hip osteoarthritis over four to five years: Data from the OAI and CHECK studies.

Salis Z Osteoarthr Cartil Open. 2024; 6(1):100427.

PMID: 38187099 PMC: 10770760. DOI: 10.1016/j.ocarto.2023.100427.


Development of Prediction Model Using Machine-Learning Algorithms for Nonsteroidal Anti-inflammatory Drug-Induced Gastric Ulcer in Osteoarthritis Patients: Retrospective Cohort Study of a Nationwide South Korean Cohort.

Jeong J, Han H, Ro D, Han H, Won S Clin Orthop Surg. 2023; 15(4):678-689.

PMID: 37529187 PMC: 10375806. DOI: 10.4055/cios22240.


[Concept for integrative pain treatment of osteoarthritis of the knee based on the evidence for conservative and complementary therapies].

Irnich D, Baumler P Schmerz. 2023; 37(6):413-425.

PMID: 37505229 DOI: 10.1007/s00482-023-00739-0.